Developer docs
API playgroundTry for free, no card

Search company profiles

Demetrix

Full company profile

uuid000249g

Namestring
Demetrix
Websiteurl
demetrixbio.com
Company typeenum
Private
Founded yearint
2017
Short descriptiontext

Demetrix is a Berkeley-based biotechnology company founded in 2017 that researches and produces bioactive ingredients via fermentation-based synthetic biology. It is led by CEO Jeff Ubersax and co-founders Jay Keasling and William Haseltine, and has raised approximately $61M from biotech-oriented venture investors.

Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBerkeley, United States
HQ citystring
Berkeley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biotechnology research, bioactive ingredients, biomanufacturing, synthetic biology, fermentation technology
Industry1 code
1Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
CodeHLAAAIADPrimaryYes
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Bioactive Ingredients
Social media profiles2 records
Cost components4 values
Personnel, Technology or R&D, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Demetrix is a biotechnology company that researches and produces bioactive ingredients. The company applies biotechnology research and bioprocess development to manufacture bioactive ingredient products intended for downstream use by other businesses in applicable industries.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Bioactive ingredients
CategoryBioactive Ingredients
Description

Bioactive ingredients researched and produced by Demetrix using biotechnology processes, intended for downstream business customers that incorporate such ingredients into formulated end products.

No data
Peers10 records
1Codexis
TypeOthers
2Zymergen
TypeDirect peer
Description

Synthetic biology company combining automation and engineered microbes to develop bioproducts, also with Berkeley roots and similarly affected by the broader downturn in synthetic biology equities — a cautionary comparable for Demetrix's path.

3Conagen
TypeDirect peer
Description

Synthetic biology company that engineers microbes to produce high-value bioactive ingredients, including rare molecules and flavors/fragrances. Closely comparable to Demetrix in fermentation approach and bioactive ingredient output.

4International Flavors & Fragrances (IFF)
TypeBroad incumbent
Description

Major flavors, fragrances, and bioactive ingredients company with a Health & Biosciences division built partly through fermentation acquisitions. Represents the kind of strategic acquirer relevant to Demetrix's likely exit path.

5Ginkgo Bioworks
TypeDirect peer
Description

Cell engineering and synthetic biology platform that programs organisms for ingredient and bioproduct applications. Comparable as a synthetic biology peer that similarly targeted ingredient and bioproduct customers via engineered organisms.

6Novonesis (Novozymes)
TypeBroad incumbent
Description

Global leader in industrial enzymes and microbial protein ingredients, serving food, beverage, and consumer health markets. Comparable as a broad incumbent in fermentation-derived bioactive ingredients that Demetrix's customers would also engage.

7Twist Bioscience
TypeEmerging player
Description

Synthetic biology company offering DNA synthesis and engineered biological tools, with adjacent efforts in biologic and ingredient discovery. Adjacent peer due to synthetic biology technology overlap with Demetrix's chassis/pathway engineering needs.

8DSM-Firmenich
TypeBroad incumbent
Description

Global nutrition, health, and flavors/fragrances group with active fermentation and synthetic biology sourcing programs. Comparable as a potential strategic acquirer for Demetrix-class bioactive ingredient platforms.

9Amyris
TypeDirect peer
Description

Fermentation-based ingredients company also founded by Jay Keasling out of UC Berkeley/JBEI; produces specialty ingredients via engineered yeast. Most direct comparable to Demetrix in technology, founder lineage, and ingredient focus, though broader in product scope.

10LanzaTech
TypeEmerging player
Description

Gas fermentation company using engineered microbes to convert waste gases into fuels and chemicals, including ingredients. Comparable as a fermentation-based synthetic biology company producing novel ingredients at industrial scale.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Demetrix

Bioactive Ingredientsdemetrixbio.com

Demetrix is a Berkeley-based biotechnology company founded in 2017 that researches and produces bioactive ingredients via fermentation-based synthetic biology. It is led by CEO Jeff Ubersax and co-founders Jay Keasling and William Haseltine, and has raised approximately $61M from biotech-oriented venture investors.

Demetrix firmographics

Firmographics
Name
Demetrix
Website
https://demetrixbio.com
Company type
Private
Founded year
2017
Headcount range
51–100 employees
Short description
Demetrix is a Berkeley-based biotechnology company founded in 2017 that researches and produces bioactive ingredients via fermentation-based synthetic biology. It is led by CEO Jeff Ubersax and co-founders Jay Keasling and William Haseltine, and has raised approximately $61M from biotech-oriented venture investors.
Ownership category
akta.pro rank

Demetrix industry classification

Industry
Product category
Bioactive Ingredients
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro primary industry
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

  • Biotechnology research
  • Bioactive ingredients
  • Biomanufacturing
  • Synthetic biology
  • Fermentation technology

Where Demetrix is headquartered

Location

Headquarters

HQ city
Berkeley
HQ country
United States
HQ region
North America

Markets served

Demetrix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain

Demetrix product offering

Product offering

Core offering

Demetrix is a biotechnology company that researches and produces bioactive ingredients. The company applies biotechnology research and bioprocess development to manufacture bioactive ingredient products intended for downstream use by other businesses in applicable industries.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bioactive ingredients Bioactive ingredients researched and produced by Demetrix using biotechnology processes, intended for downstream business customers that incorporate such ingredients into formulated end products.

Companies that use Demetrix

Customer profile

Ideal customer profiles1 record

Demetrix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Demetrix competitors and assessment

Company assessment

Others

Direct peers

  • Zymergen: Synthetic biology company combining automation and engineered microbes to develop bioproducts, also with Berkeley roots and similarly affected by the broader downturn in synthetic biology equities — a cautionary comparable for Demetrix's path.
  • Conagen: Synthetic biology company that engineers microbes to produce high-value bioactive ingredients, including rare molecules and flavors/fragrances. Closely comparable to Demetrix in fermentation approach and bioactive ingredient output.
  • Ginkgo Bioworks: Cell engineering and synthetic biology platform that programs organisms for ingredient and bioproduct applications. Comparable as a synthetic biology peer that similarly targeted ingredient and bioproduct customers via engineered organisms.
  • Amyris: Fermentation-based ingredients company also founded by Jay Keasling out of UC Berkeley/JBEI; produces specialty ingredients via engineered yeast. Most direct comparable to Demetrix in technology, founder lineage, and ingredient focus, though broader in product scope.

Broad incumbents

  • International Flavors & Fragrances (IFF): Major flavors, fragrances, and bioactive ingredients company with a Health & Biosciences division built partly through fermentation acquisitions. Represents the kind of strategic acquirer relevant to Demetrix's likely exit path.
  • Novonesis (Novozymes): Global leader in industrial enzymes and microbial protein ingredients, serving food, beverage, and consumer health markets. Comparable as a broad incumbent in fermentation-derived bioactive ingredients that Demetrix's customers would also engage.
  • DSM-Firmenich: Global nutrition, health, and flavors/fragrances group with active fermentation and synthetic biology sourcing programs. Comparable as a potential strategic acquirer for Demetrix-class bioactive ingredient platforms.

Emerging players

  • Twist Bioscience: Synthetic biology company offering DNA synthesis and engineered biological tools, with adjacent efforts in biologic and ingredient discovery. Adjacent peer due to synthetic biology technology overlap with Demetrix's chassis/pathway engineering needs.
  • LanzaTech: Gas fermentation company using engineered microbes to convert waste gases into fuels and chemicals, including ingredients. Comparable as a fermentation-based synthetic biology company producing novel ingredients at industrial scale.

Market position

Customer concentration

Demetrix social profiles

Digital presence

Demetrix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Demetrix leadership team

Management profile

Number of profiles

Profiles3 records

Demetrix funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Demetrix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Demetrix

What does Demetrix do?

Demetrix is a biotechnology company that researches and produces bioactive ingredients. The company applies biotechnology research and bioprocess development to manufacture bioactive ingredient products intended for downstream use by other businesses in applicable industries.

When was Demetrix founded?

Demetrix was founded in 2017. It employs 51 to 100 people.

Where is Demetrix based?

Demetrix is headquartered in Berkeley, United States, in the North America region.

Who are Demetrix's main competitors?

Codexis is listed as an others. Direct peers are Zymergen, Conagen, Ginkgo Bioworks and Amyris. Broad incumbents are International Flavors & Fragrances (IFF), Novonesis (Novozymes) and DSM-Firmenich. Emerging players are Twist Bioscience and LanzaTech.

Does Demetrix have an API?

No public API is recorded for Demetrix.

What industry is Demetrix in?

Demetrix's product category is Bioactive Ingredients. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TracxnTop Companies in Cannabis Based Nutraceuticals (Jan, 2025)The article presents a ranked list of top startups in the cannabis-based nutraceuticals sector, including Demetrix, Vireo Health, Equilibria, and Nutritional High. It provides specific operational details for these entities, such as their founding years, locations, funding stages, and total capital raised. The text also notes that an average of 142 new companies in this niche are launched annually.PR NewswireDEMETRIX INITIATES 2022 COMMERCIAL MANUFACTURING CAMPAIGNDemetrix, a biotechnology company based in Berkeley, California, has initiated its 2022 commercial manufacturing campaign to produce and sell CBG (cannabigerol), a rare cannabinoid. Initial global customers in personal care and nutrition segments have committed to purchasing approximately 70% of the company's total production, which is expected to generate multi-million dollars of revenue in 2022. The company achieved commercial-scale production in approximately three years, marking the first time a biosynthesis company in the cannabinoids space has accomplished this milestone in such a short timeframe.BenzingaThe Bio Revolution of Medical Cannabinoid TherapeuticsThis analysis piece discusses the emerging field of biosynthesized cannabinoids, describing how companies are engineering organisms like yeast and bacteria to produce cannabinoids through fermentation, potentially offering higher quality and lower cost production than traditional cannabis cultivation. The article identifies several companies competing in this space—Demetrix, Cronos, CREO, Willow Bio, and Biomedican—while noting that Biomedican currently leads with 5% dry cell mass yields and production costs under $1 per gram. Aurora Cannabis and Biomedican are identified as the only two companies holding patents for Olivetolic Acid, a critical component in cannabinoid biosynthesis.ObserverCannabinoids Are the Next Big Thing in the Pot Industry, But Who Can Mass-Produce It?The startup Demetrix is preparing to manufacture large quantities of cannabigerol (CBG) in Berkeley, California, with products expected by the end of the year. Biomedican, another California-based startup, is also focused on rare cannabinoids and projects the industry may be worth $25 billion by 2025. Both companies utilize engineered yeast to produce these cannabinoids on a commercial scale, addressing a rising consumer interest in niche marijuana products.PR NewswireDemetrix Signs Its First Contract Manufacturing Organization For Commercial Scale Production Of Rare CannabinoidsDemetrix, Inc., a Berkeley-based biotechnology company focused on rare cannabinoids, announced it has signed its first contract manufacturing organization (CMO) partner for commercial-scale production using fermentation. The FDA-registered, food cGMP-compliant facility will enable Demetrix to produce metric tons of rare cannabinoids annually, with the first ingredient being CBG (cannabigerol). The company stated it is on track to commercialize its business later in 2021 and is currently engaging with top consumer products companies and global regulatory agencies.PR NewswireDemetrix Begins CBG Sampling For Health And Wellness ProductsDemetrix Inc., a biotechnology company based in Berkeley, California, announced the launch of a sampling program for the rare cannabinoid CBG (cannabigerol), making samples available in quantities up to tens of grams to companies developing skincare, pharmaceutical, and health and wellness products. The program follows the company's successful 15,000-liter demonstration-scale production of CBG earlier in 2020, leveraging its proprietary fermentation technology platform that produces rare cannabinoids at higher purity and lower cost than traditional plant-based extraction methods. Demetrix has secured $61 million in venture-led funding to advance its work in producing rare cannabinoids for pharmaceutical and consumer applications.CbdtestersWill Legal Synthetic Cannabinoids Take Over Cannabis Industry?Biotech and pharmaceutical companies including Willow Biosciences, Biomedican Inc., Demetrix, and Amyris are developing legal synthetic cannabinoids like CBG to compete with plant-derived cannabis. These entities aim to leverage mass production capabilities and patent protections to potentially co-opt the medical marijuana market by offering lower-cost alternatives. The article highlights the strategic shift from natural extraction to synthetic creation as a method for controlling intellectual property and reducing manufacturing expenses.AxiosStartups want to biosynthesize CBDStartups are competing to use biosynthesis, a process that engineers microbes to produce cannabinoids like CBD, as a cheaper and more controllable alternative to traditional plant cultivation. The global cannabinoid biosynthesis market opportunity is estimated at $40 billion, with companies aiming to overcome the high costs and regulatory hurdles associated with growing cannabis plants. Key players include Demetrix and Biomedican, which are transitioning from demo-scale efforts to full-scale production.PR NewswireDemetrix Secures $50 Million In Series A Funding To Provide Cannabinoids To Pharmaceutical, Supplement, And Consumer Product CompaniesDemetrix Inc., a California-based biotechnology company focused on cannabinoid production, secured $50 million in Series A funding led by Tuatara Capital with participation from existing investor Horizons Ventures. The funding will be used to scale operations and commercialize the first of more than 100 unique cannabinoids using the company's fermentation technology with baker's yeast, which produces high purity cannabinoids at lower cost compared to traditional plant extraction. Demetrix has now raised over $60 million in total funding and is working with global regulatory organizations to bring these compounds to pharmaceutical, supplement, and consumer product markets.VC News DailyDemetrix Scores $50M Series ADemetrix, a biotechnology company specializing in cannabinoid production using yeast fermentation, announced the closing of a $50 million Series A funding round led by Tuatara Capital with participation from existing investor Horizons Ventures. The company intends to use the capital to scale operations and commercialize the first of more than 100 unique cannabinoids, leveraging its fermentation technology that produces high-purity cannabinoids at lower cost compared to traditional plant extraction. The investment signals continued venture capital interest in the legal cannabis industry's supply chain innovation.